Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elaina Chu"'
Autor:
Lawrence H. Schwartz, Barbara MacGregore-Cortelli, Lee M. Krug, Howard I. Scher, Stacy Richardson, Mark L. Heaney, Semra Olgac, Tracy Curley, Elaina Chu, Victoria M. Richon, J. Paul Secrist, William P. Tong, Owen A. O'Connor, Judy H. Chiao, Paul A. Marks, William Kevin Kelly
Publikováno v:
Journal of Clinical Oncology. 23:3923-3931
Purpose To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer. Patients and Methods Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de575261fe083dad57ecfeee2edebb3b
https://doi.org/10.1200/jco.2005.14.167
https://doi.org/10.1200/jco.2005.14.167
Autor:
Lawrence H. Schwartz, Steven M. Larson, David Verbel, Marisa Ditullio, Karen L. Siedlecki, Glenn Heller, Tim Akhurst, Howard I. Scher, Elaina Chu, W. Kevin Kelly, Susan F. Slovin, Michael J. Morris
Publikováno v:
Clinical Cancer Research. 11:3210-3216
Purpose: Standard imaging studies are limited as outcome measures for patients with metastatic prostate cancer. We tested the hypothesis that serial fluorodeoxyglucose positron emission tomography (FDG-PET) scans can serve as an outcome measure for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62bf76399af8915b264dbb86cc81aaf4
https://doi.org/10.1158/1078-0432.ccr-04-2034
https://doi.org/10.1158/1078-0432.ccr-04-2034
Publikováno v:
Cancer letters. 131(1)
Degradation of extracellular matrix by hyaluronidase increases murine L929 cell sensitivity to tumor necrosis factor (TNF) cytotoxicity. Seeding and culturing L929 cells onto the matrix of serum fetuin and the hyaluronate-binding inter-alpha-inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65932dca529135f5b7486716496f82e6
https://pubmed.ncbi.nlm.nih.gov/9839619
https://pubmed.ncbi.nlm.nih.gov/9839619
Autor:
K. W. Beekman, Tracy Curley, David R. Shaffer, Anthony Delacruz, Howard I. Scher, C. Eicher, Elaina Chu, Wm. Kevin Kelly, Susan F. Slovin, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 23:4633-4633
4633 Background: Bortezomib (VELCADE, Millennium Pharmaceuticals, Cambridge, MA) is a proteasome inhibitor that induced PSA declines in patients (pts) with castrate metastatic PC in phase I studies...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42c8511a3ea3cad7b2ec11ca009d79f2
https://doi.org/10.1200/jco.2005.23.16_suppl.4633
https://doi.org/10.1200/jco.2005.23.16_suppl.4633